Gail Javitt, JD, MPH


1227 25th St NW
Washington, DC 20037

Ms. Javitt has served as an adjunct professor of law at the University of Maryland School of Law, where she has taught Food and Drug Law and Genetics and Law, and at the Johns Hopkins School of Public Health, where she co-taught Health Law and Regulation. She was a Greenwall Fellow in Bioethics and Health Policy at Johns Hopkins and Georgetown Universities. She was an Associate at Covington & Burling in Washington, D.C., where she specialized in FDA regulatory issues. She served as law clerk to the Honorable Gary L. Taylor, U.S. District Court, Central District of California. She has written on a variety of science regulatory and legal issues on topics including direct-to-consumer advertising of genetic testing and FDA regulation of biotechnology. She holds the Juris Doctor (J.D.), cum laude, from Harvard Law School, a Masters of Public Health (M.P.H.) from the Johns Hopkins University and a B.A., magna cum laude, Phi Beta Kappa, from Columbia College.

Research Interests

  • Science regulatory and legal issues
  • Direct-to-consumer advertising of genetic testing
  • FDA regulation of biotechnology


  • J.D., Harvard Law School
  • M.P.H., Johns Hopkins University
  • B.A.,  Columbia College

Recent Publications

1: Javitt, G. (2010). Which way for genetic-test regulation? Assign regulation appropriate to the level of risk. Nature466(7308), 817-818.

2: Hudson, K., & Javitt, G. (2009). Regulating laboratory-developed tests. Nature biotechnology27(5), 419-420.

3: Hogarth, S., Javitt, G., & Melzer, D. (2008). The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu. Rev. Genomics Hum. Genet.9, 161-182.

4: Javitt, G., Berkowitz, D., & Gostin, L. O. (2008). Assessing mandatory HPV vaccination: who should call the shots? The Journal of Law, Medicine & Ethics36(2), 384-395.

5: Javitt, G. H. (2007). In search of a coherent framework: options for FDA oversight of genetic tests. Food & drug LJ62, 617.

6: Javitt, G. (2007). FDA and clinical labs: beginning a dialogue. MLO: medical laboratory observer39(5), 52-50.